中藥材黃連組成物對肺癌及肝癌放射線治療動物模式之免疫調控因子基因表現

成佳憲
台大醫院
本研究之目的為釐清中藥材黃連應用於腫瘤放射線治療在免疫調控層次的適切性。先前的研究中我們已經由動物模式研究發現黃連併用給予能降低腫瘤放射線治療誘發小鼠血清中IL-6及PGE-2的上升，對於照射部位的皮膚損傷與掉毛的反應也有延緩的作用。細胞學的研究結果也顯示，黃連萃取物在無細胞毒性的劑量下對於由VEGF誘發血管內皮細胞的生長、通透性、移行能力、管狀型態形成能力等血管新生作用皆具有部分抑制效果，對於Akt及ERK的磷酸化作用及NF-kB leuciferase reporter的活化等訊息傳遞等分子層次現象，也具有部分抑制效果，然而由於黃連為混合物，因此其組成物中應具有對抑制上述細胞反應或分子層次效應更有效力的分子，值得進一步探討。近年來免疫調控反應逐漸被研究發現與腫瘤惡性化有密切關連，而TNF-alpha、IL-1beta、IL-6及PGE-2是已知免疫調控機制上重要的分子，因此，我們認為釐清黃連抗發炎的組成分及其作用機轉，將對黃連在併用於腫瘤之治療具有重要意義。在研究方法上，本研究主要將以肺癌及肝癌放射線治療動物模式，配合細胞分子生物學方法探討中藥材黃連組成物對免疫調控因子基因表現之調控，並以人類細胞株進行驗證。
關鍵字：中藥材；黃連；肺癌；肝癌；免疫調控；放射線治療

Effects of Chinese herb Coptis chinensis?s components on inflammatory cytokine regulation in animal models with radiotherapy to lung cancer and hepatoma

Chia-Hsien Cheng
National Taiwan University Hospita
Radiation biology experiment is the best model for the adjunct therapeutic test, because of its safe, noninvasive characteristics and effectiveness. In radiation model we do not have to consider the interaction between the test drug and the other drugs. In radiation biology for cancer, the ways to enhance cancer cell sensitization and to reduce the damage of normal tissue from radiation are the most important issues to be addressed. Inflammation is being highly recognized as one of the keys to these two physiological responses. On the other hand, radiotherapy induced inflammation may be beneficial for tumor cells but harmful for normal tissue. This concept has been accepted and several clinical trials of anti-inflammatory drug combined radiotherapy are ongoing. Ten pure componenets have neen isolated and identified from Chinese herb Coptis chinensis. In this study, we will test their potential role of adjunct therapeutic effect in combination with radiotherapy on cancer treatment. In this study we investigated the adjunct therapeutic effect of the ten pure componenets in hepatoma and lung cancer animal model and evaluate the anti-inflammation effect by detecting serum level TNF-alpha, IL-1beta, IL-6 and PGE2.
關鍵字：Chinese herb；Coptis chinensis；lung cancer；hepatoma；Immune regulation；radiotherapy